Assessment of inhibitor risk after switching from plasma-derived factor VIII concentrate to recombinant factor VIII (Brasil-RFVIII: brazilian study of inhibitor linked to recombinant factor VIII)

被引：0
|
作者：
Prezotti, A. [1 ,2 ]
Montalvao, S. [1 ]
Marques, A. [3 ]
Ferreira, C. [4 ]
Oliveira, L. [5 ]
Villaca, P. [6 ]
Ferreira Filho, L. [7 ]
Lorenzato, C. [8 ]
Medina, S. [1 ]
Araujo, F. [9 ]
Ozelo, M. [1 ]
机构：
[1] Univ Campinas UNICAMP, INCT SANGUE HEMOCTR UNICAMP, Campinas, SP, Brazil
[2] Hemoctr Espirito Santo, Hematol, Vitoria, Brazil
[3] HEMORIO, Hematol, Rio De Janeiro, Brazil
[4] Hemoctr Rio Grande do Sul HEMORS, Hematol, Porto Alegre, RS, Brazil
[5] Univ Sao Paulo USP Ribeirao Preto, Hemoctr Ribeirao Preto, Ribeirao Preto, Brazil
[6] HCFMUSP Univ Sao Paulo, Hematol, Sao Paulo, Brazil
[7] HEMOCTR CEARA HEMOCE, Hematol, Fortaleza, Ceara, Brazil
[8] HEMOCTR PARANA HEMEPAR, Hematol, Curitiba, Parana, Brazil
[9] Hemoctr Pernambuco HEMOPE, Hematol, Recife, PE, Brazil
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO286-MON
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [21] Determination of the factor VIII plasma activity of hemophilia a patients treated with a new recombinant factor VIII concentrate
    von Pape, KW
    Klamroth, R
    Kyank, U
    Bohner, J
    35TH HEMOPHILIA SYMPOSIUM, 2006, : 153 - +
  • [22] Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates
    Dingli, D
    Gastineau, DA
    Gilchrist, GS
    Nichols, WL
    Wilke, JL
    HAEMOPHILIA, 2002, 8 (05) : 629 - 634
  • [23] FACTOR-VIII INHIBITOR ASSAYS USING PLASMA-DERIVED FVIII VERSUS RECOMBINANT FVIII - A COMPARATIVE-STUDY
    HILLMANWISEMAN, C
    VITALE, C
    LUSHER, J
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 684 - 684
  • [24] Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro
    Astermark, J
    Voorberg, J
    Lenk, H
    Dimichele, D
    Shapiro, A
    Tjönnfjord, G
    Berntorp, E
    HAEMOPHILIA, 2003, 9 (05) : 567 - 572
  • [25] Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better
    Mannucci, Pier Mannuccio
    BLOOD TRANSFUSION, 2010, 8 (04) : 288 - 291
  • [26] Comparative stability of plasma derived and recombinant factor VIII
    Mankarious, S
    Parti, R
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2077 - P2077
  • [27] Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study
    Miri, Syna
    Rosendaal, Frits R.
    Kavakli, Kaan
    Eshghi, Peyman
    Moghaddam, Soha Mohammadi
    Scardo, Sara
    Habibpanah, Behnaz
    Elalfy, Mohsen
    Halimeh, Susan
    Nicolo, Gabriella
    Gokcebay, Dilek
    Ozbek, Namik
    Celkan, Tiraje
    Mohammadi, Ahmad
    Karimi, Mehran
    Shahsavani, Amin
    Yilmaz, Baris
    Albayrak, Canan
    Gunes, Burcak
    Kaya, Zuehre
    Ay, Yilmaz
    Akbayram, Sinan
    Sarper, Nazan
    Mannucci, Pier Mannuccio
    Peyvandi, Flora
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (08)
  • [28] RECENT ADVANCES IN THE PREPARATION OF PLASMA-DERIVED AND RECOMBINANT COAGULATION FACTOR-VIII
    BRAY, GL
    JOURNAL OF PEDIATRICS, 1990, 117 (03): : 503 - 507
  • [29] Biochemical and immunochemical investigations of different plasma-derived and recombinant factor VIII products
    Josic, D
    Stadler, M
    Buchacher, A
    Schulz, P
    Schutz, R
    Wiry, G
    Schwinn, H
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2095 - P2095
  • [30] RECOMBINANT AND PLASMA-DERIVED FACTOR-VIIA DO NOT CORRECT BLEEDING-TIME IN A RABBIT FACTOR-VIII INHIBITOR MODEL
    TURECEK, PL
    SCHWARZ, HP
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 986 - 986
12345